In tumor cells not expressing QPCTL, there is reduced pyroglutamination in CD47- SIRPα binding and enhanced macrophage phagocytosis of tumor cells.1051,1052 Phase 1 or 2a studies evaluating QPCT or QPCTL inhibitors for neurodegenerative diseases reported no significant toxicity. This evidence concerns the gene CD47 and neoplasm.